

## PRODUCT INFORMATION

|   |   |
|---|---|
| <b>Common Name</b>                      | VAY-736   |
| <b>Conjugate</b>                        | PE-conjugated   |
| <b>Synonyms</b>                         | BAFFR;TNFRSF13C;BAFF-R;BROMIX;CD268;CVID4;prolixin  |
| <b>Applications</b>                     | Flow Cyt  |
| <b>Recommended Dilutions</b>            | Flow Cyt 1µl/test   |
| <b>Formulation &amp; Reconstitution</b> | Liquid□PBS with,0.18%BSA□0.1%Proclin300   |
| <b>Host Species</b>                     | Homo sapiens  |
| <b>IgG type</b>                         | Human IgG1 - kappa  |
| <b>Reactivity</b>                       | Human   |
| <b>Target</b>                           | BAFF-R  |
| <b>Uniprot ID</b>                       | Q96RJ3  |
| <b>Description</b>                      | PE-conjugated Anti-BAFFR (ianalumab biosimilar) mAb   |
| <b>Delivery</b>                         | In Stock  |
| <b>Storage&amp;Shipping</b>             | Store at 2°C-8°C for 6 months   |
| <b>Background</b>                       | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| <b>Usage</b>                            | Research use only   |

DIMABIO CONFIDENTIAL






Figure 1. Flow cytometry analysis with 1  $\mu$ l/test PE-conjugated Anti-BAFFR(ianalumab biosimilar) on HEK293 cells transfected with Human BAFFR protein (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).

